Clinical Trial Update: An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 exploratory trial evaluating pembrolizumab in combination with entinostat for non-inflamed stage III/IV melanoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Entinostat (entinostat)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2024-01-10